4.7 Article

Synthesis and antiplasmodial activity of regioisomers and epimers of second-generation dual acting ivermectin hybrids

Journal

SCIENTIFIC REPORTS
Volume 12, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41598-021-04532-w

Keywords

-

Funding

  1. SERB, DST [EMR/2017/000520]
  2. Guru Nanak Dev University, Amritsar
  3. FundacAo para a Ciencia e Tecnologia, Portugal [PTDC-SAU-INF-29550/2017]
  4. University Grants Commission (UGC), New Delhi
  5. Fundação para a Ciência e a Tecnologia [PTDC/SAU-INF/29550/2017] Funding Source: FCT

Ask authors/readers for more resources

With its strong impact on vector-borne diseases and malaria, ivermectin has been proven to be a promising antimalarial therapeutic. By modifying the structure of ivermectin and combining it with existing antimalarial agents, novel molecular hybrids with enhanced activity against Plasmodium parasites have been developed. These compounds displayed structure-dependent antiplasmodial activity, outperforming ivermectin itself, suggesting the superiority of this hybridization strategy in designing new antimalarial agents.
With its strong effect on vector-borne diseases, and insecticidal effect on mosquito vectors of malaria, inhibition of sporogonic and blood-stage development of Plasmodium falciparum, as well as in vitro and in vivo impairment of the P. berghei development inside hepatocytes, ivermectin (IVM) continues to represent an antimalarial therapeutic worthy of investigation. The in vitro activity of the first-generation IVM hybrids synthesized by appending the IVM macrolide with heterocyclic and organometallic antimalarial pharmacophores, against the blood-stage and liver-stage infections by Plasmodium parasites prompted us to design second-generation molecular hybrids of IVM. Here, a structural modification of IVM to produce novel molecular hybrids by using sub-structures of 4- and 8-aminoquinolines, the time-tested antiplasmodial agents used for treating the blood and hepatic stage of Plasmodium infections, respectively, is presented. Successful isolation of regioisomers and epimers has been demonstrated, and the evaluation of their in vitro antiplasmodial activity against both the blood stages of P. falciparum and the hepatic stages of P. berghei have been undertaken. These compounds displayed structure-dependent antiplasmodial activity, in the nM range, which was more potent than that of IVM, its aglycon or primaquine, highlighting the superiority of this hybridization strategy in designing new antiplasmodial agents.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available